Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3‐ITD status: a report from the Children's Oncology Group. (25th March 2014)

• Record Type: Journal Article
• Authors: Tarlock, Katherine; Alonzo, Todd A.; Moraleda, Pilar P.; Gerbing, Robert B.; Raimondi, Susana C.; Hirsch, Betsy A.; Ravindranath, Yaddanapudi; Lange, Beverly; Woods, William G.; Gamis, Alan S.; Meshinchi, Soheil
• Is Part Of: British journal of haematology. Volume 166:Number 2(2014:Jul.)
• Page Start: 254
• Page End: 259
• Publication Date: 2014-03-25
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12852
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh12852-abs-0001"> <title>Summary</title> <p>Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a rare subtype associated with <italic>FLT3</italic>‐internal tandem duplication (ITD) and poor outcomes. The clinical outcomes of paediatric patients with t(6;9) with and without <italic>FLT3</italic>‐ITD treated on six consecutive cooperative trails were evaluated. In contrast to patients without t(6;9), those with t(6;9) had a significantly lower complete remission rate, higher relapse rate (RR), and poor overall survival (OS). Within t(6;9) patients, those with and without <italic>FLT3</italic>‐ITD had an OS of 40% and 27% respectively (<italic>P</italic> &gt; 0·9), demonstrating that t(6;9) is a high‐risk cytogenetic feature in paediatric AML and its clinical impact is independent of the presence of <italic>FLT3</italic>‐ITD.</p> </abstract>